Literature DB >> 14714552

Acute cutaneous barrier disruption activates epidermal p44/42 and p38 mitogen-activated protein kinases in human and hairless guinea pig skin.

Hiromi Kobayashi1, Setsuya Aiba, Yumiko Yoshino, Hachiro Tagami.   

Abstract

Acute cutaneous barrier disruption of the skin elicits various homeostatic repair responses in the epidermis. Although several candidates for the signaling mechanisms that induce these responses have been reported, e.g. the calcium and ion concentration, peroxisome proliferator-activated receptor-alpha, and TNF-alpha signaling mediated by sphingomyelinases, the exact nature of the signals remains undertermined. Therefore, assuming that an important group of serine/threonine-signaling kinases, mitogen- and SAPK/JNK, might link the barrier disruption to the subsequent homeostatic responses, the activation of three MAPKs in hairless guinea pig or in human skin after barrier disruption was investigated. The epidermal barrier was insulated with tape stripping or organic solvents, and Western blotting, and immune complex kinase assay. In the skin of hairless guinea pigs, p44/42 MAPK and p38 MAPK, but nor SAPK/JNK, were continued to be activated for at least 180 min. The activation of p44/42 which positively correlated with the number of tape strippings, whereas K+ sucrose solution suppressed its activation. The activation of p44/42 MAPK was also induced by treatment of the skin with organic solvents. In similar fashion, p44/42 and p38 MAPKs were found to be activated in human skin after tape stripping. These results for strongly suggest that the activation of p44/42 and p38 MAPKs links the stimuli of barrier disruption to the subsequent homeostatic responses to repair the barrier defect.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14714552     DOI: 10.1111/j.0906-6705.2003.00045.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  8 in total

Review 1.  Wound repair at a glance.

Authors:  Tanya J Shaw; Paul Martin
Journal:  J Cell Sci       Date:  2009-09-15       Impact factor: 5.285

2.  Development of atopic dermatitis-like skin disease from the chronic loss of epidermal caspase-8.

Authors:  Christopher Li; Samuel Lasse; Pedro Lee; Manando Nakasaki; Shih-Wei Chen; Kenshi Yamasaki; Richard L Gallo; Colin Jamora
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-06       Impact factor: 11.205

3.  Knockdown of filaggrin influences the epidermal terminal differentiation via MAPK pathway in normal human epidermal keratinocytes.

Authors:  Ningning Dang; Shuguang Pang; Haiyan Song; Hong Bian; Xiaoran Zhang; Liguo An; Xiaoli Ma
Journal:  Mol Biol Rep       Date:  2014-11-06       Impact factor: 2.316

Review 4.  Cell migration.

Authors:  Xavier Trepat; Zaozao Chen; Ken Jacobson
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

5.  Cdc42 inhibits ERK-mediated collagenase-1 (MMP-1) expression in collagen-activated human keratinocytes.

Authors:  Maryam G Rohani; Brian K Pilcher; Peter Chen; William C Parks
Journal:  J Invest Dermatol       Date:  2013-11-25       Impact factor: 8.551

6.  Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects.

Authors:  Helena Escuin-Ordinas; Yining Liu; Lu Sun; Willy Hugo; Robert Dimatteo; Rong Rong Huang; Paige Krystofinski; Ariel Azhdam; Jordan Lee; Begoña Comin-Anduix; Alistair J Cochran; Roger S Lo; Tatiana Segura; Philip O Scumpia; Antoni Ribas
Journal:  PLoS One       Date:  2021-06-23       Impact factor: 3.240

7.  ERK activating peptide, AES16-2M promotes wound healing through accelerating migration of keratinocytes.

Authors:  Sora Lee; Myun Soo Kim; Su-Jin Jung; Daejin Kim; Hyun Jeong Park; Daeho Cho
Journal:  Sci Rep       Date:  2018-09-26       Impact factor: 4.379

8.  MAPK Pathway Involved in Epidermal Terminal Differentiation of Normal Human Epidermal Keratinocytes.

Authors:  Xianguang Meng; Liyun Qiu; Haiyan Song; Ningning Dang
Journal:  Open Med (Wars)       Date:  2018-05-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.